Artificial Intelligence in Drug Discovery Market: Growth, Size, Share, and Trends

Report Code HIT 7445
Published in Nov, 2024, By MarketsandMarkets™
Download PDF

Choose License Type

Buy Report Now Inquire Before Buying

Artificial Intelligence in Drug Discovery Market by Process (Target, Lead), Use Case (Design & Optimisation: Vaccine, Antibody; Disease understanding, PK/PD), Therapy (Cancer, CNS, CVS), Tool (ML:DL (CNN, GAN)), End User & Region - Global Forecast to 2029

Overview

The global AI in drug discovery market is expected to reach USD 6.89 billion by 2029 from USD 1.86 billion in 2024, at a CAGR of 29.9% during the forecast period. Standardization of diverse datasets generated from sources like clinical trials, genomics, and real-world evidence to efficiently exchange of information across various platforms & geographical regions, enhancing research collaboration between tech companies and pharmaceutical firms, emergence of technologies like AI, quantum computing, cognitive computing that harness large volumes of raw data into actionable insights, innovative solutions and targeted therapies, and leveraging diverse datasets like genetic, clinical, and chemical data to deliver insights, emphasize in the development for rare and orphan drugs, finding new drug candidates, etc., to reduce the workload on researchers & investigators are some of the prominent factors that contribute to the constantly increasing adoption of AI in drug discovery market.

Attractive Opportunities in the AI in Drug Discovery Market

North America

Well-established pharmaceutical industry, high focus on R&D, and the presence of leading pharmaceutical companies are boosting the market in North America.

The growth of this market is primarily driven by the growing number of cross-industry collaborations and partnerships, the need to control drug discovery & development costs and reduce the overall time taken in this process, and the increasing focus on oncology indication.

Lack of suitable datasets to feed AI models, lack of access to proprietary databases, limited interoperability of existing datasets, lack of mature tools, and limited tool usability may hamper the growth of the market.

The European AI in drug discovery market is expected to be worth USD 1,965.9 million by 2029, growing at CAGR of 29.8% during the forecast period.

Increasing focus on precision medicine, growing biotechnology industry, and focus on developing human-aware AI systems, increasing adoption of AI-enabled single cell analysis offer several opportunities for market growth.

Global AI in Drug Discovery Market Dynamics

DRIVER: Growing cross-industry collaborations and partnerships

With the growing awareness of the benefits of AI and its application areas, the adoption of AI technology in drug discovery has increased.

Pharmaceutical and biotechnology companies are embracing AI on multiple fronts, from drug discovery and clinical development to safety monitoring and risk assessment. Major companies are entering into strategic collaborations and partnerships with the key players operating in the AI field. Such strategies enable these market players to offer highly sophisticated solutions, that is, AI-based drug discovery platforms, and ensure a more robust position in this volatile market space.

Companies in the AI drug discovery market are using both internal and external strategies to improve their drug development processes with cutting-edge technology. For example, in September 2023, Merck teamed up with BenevolentAI UK to take advantage of BenevolentAI's powerful AI platform and collaborate with a team of experts from various fields in drug discovery. Their goal is to identify promising candidates from the preclinical stage and begin developing innovative compounds. Similarly in September 2023, Intelligent OMICS Ltd and Janssen Research & Development, LLC ("Janssen") will co-develop Intellomx's proprietary AI platform combining multi-omics data merged with deep learning algorithms to identify novel mechanisms of disease and new therapeutic opportunities for treatment using Janssen research and development expertise in both data science and oncology. Owing to the growing demand for novel AI-based techniques in drug discovery, such developments are helping companies gain momentum in developing advanced AI-based products and tools. In January 2023, BioNTech completed the acquisition of InstaDeep for USD 440 milion. This acquisition will strengthen BioNTech position in the field of AI-powered drug discovery, design and development. Additionally, it will add ~290 highly skilled professionals to BioNTech, including experts in AI, machine learning, bioengineering, data science, and software development.

RESTRAINT: Shortage of AI workforce and ambiguous regulatory guidelines for medical software

AI is a sophisticated system that requires an employee with certain skill sets for developing, managing, and implementing it. For instance, the human resources operating with AI systems should be aware of other technologies like cognitive computing, ML and machine intelligence, deep learning, and image recognition. This is also a challenging process to integrate AI solutions with existing systems, which involve intricate processing of data to mimic the human brain activity. Even a small mistake can cause a system to fail or can adversely influence the desired outcome. The lack of professional standards and certifications in AI/ML technologies is hindering the growth of AI.

Moreover, it is intriguing for any government or regulatory agency to keep track with such fast developments and meaningfully guide the deployment of AI systems, particularly in healthcare applications. Before obtaining the approval of the FDA, AI or machine learning tools that are applicable to healthcare applications must pass tests to demonstrate that they can provide results at least as accurately as humans. For example, in Europe, software is not generally excluded; it can be assessed as a medical device if the purpose of this device is to perform a medical activity. Usually, case-by-case assessment is needed, taking into account the product characteristics, mode of use, and claims presented by the manufacturer. This assessment, however, is very complex because it is not clear from which general medical device classification, since software, unlike the abovementioned general medical devices, does not act on the human body to restore, correct, or modify such functions. Therefore, the use of software within healthcare settings is not necessarily a medical device. Such ambiguity in regulatory guidelines sometimes becomes a barrier for players.

 

OPPORTUNITY: Growing biotechnology industry

There is an ample amount of opportunities for making use of AI in drug discovery in the biotechnology industry. The private and public biotech companies total more than 2,000 in the United States, which has the largest concentration. As of 2023, IBISWorld reported 3,429 biotechnology businesses operating in the U.S. The biotech sector is becoming a leader in product and technology innovation and is essential for new product development across all biopharma companies.

Biopharmaceuticals are currently the fastest-growing segment of the pharmaceutical industry.. The reason is mainly because biopharmaceutical products are not only effective but also safe and can treat diseases that were not treatable in the past. With the growth in biotech companies, so does the overall investment in biotechnology research. This will result in larger and better-funded drug discovery efforts as this may hasten the development of new treatments. The biotechnology industry is booming and hence provides an excellent opportunity for the growth of the market for AI in drug discovery.

CHALLENGES: Computational limitations of advanced AI models

High-compute and high-storage requirements are significant for high-end AI models applied to drug discovery. This calls for significant infrastructure at a considerable cost. These models are huge data consumers and take very long training times, so most individual companies will find it impossible to obtain and train them adequately.

By financing to develop an AI infrastructure common to AI-driven drug discovery, which can be shared among various institutions, the government can overcome this problem. In this manner, advanced technologies can be availed of by other minor organizations without spending much in their systems. Besides that, through providing powerful computing resources, it may help these minor companies easily use complex AI techniques. The availability of innovative cutting-edge technology for everybody also promotes collaboration and sharing of data among the researchers themselves. Shared infrastructure investment in AI at last will help small companies get over technical barriers, bringing nearer personalized drug discovery medicine.

Global AI in Drug Discovery Market Ecosystem Analysis

The ecosystem of the AI in drug discovery market comprises investors, academic researchers/organizations, government and regulatory bodies, key players, startups, the drug discovery industry end users- pharmaceutical & biotechnology companies, contract research organizations, and research centers, academic institutes, & government organizations. The ecosystem also includes enablers such as data source providers, ERP providers, business intelligence and analytical tool providers, cloud service providers, web interface and application developers, network connectivity providers, security and privacy solutions providers, hardware providers, and consultants.

 

Pharmaceutical & biotechnology companies segment accounted for a substantial share of the AI in drug discovery market, by end user in 2023.

Pharmaceutical & biotechnology companies held the largest share of AI in the drug discovery market by end user in 2023. The significant share of this segment can be ascribed to growing demand for integration of AI and personalized medicine. The companies streamline their drug discovery processes to produce high-quality, safe products while also trying to save costs. Companies can collect and analyze all of their research data with the help of AI models to gain actionable insights in early drug discovery. Fast-track and increased precision predictions of new compounds' effectiveness and safety, which formerly took over a decade and billions of dollars in the laboratory. Consider Tempus (US) and Foundation Medicine, Inc., (US) companies developing platforms to improve cancer therapeutics and for rare disease management. They plan to provide efficient treatment of patients and minimize side effects. Together, these propel growth in the use of descriptive analytics, enabling innovation in the AI in drug discovery industry.

SAAS-based is expected to register highest growth in the AI in drug discovery market, by deployment

SaaS-based solutions are expected to register highest growth in the AI in drug discovery market the forecast period. Their growth will be mainly through increasing demand from companies in the field, which are adopting these solutions because of unlimited user support and on-demand access from anywhere, further increasing collaboration between researchers. To top this, these solutions require only a connection to the internet. This minimizes large upfront software license and hardware investments. Companies can subscribe to the extent of their needed usage. This arrangement is cloud-based, allowing online access to share and collaborate in real-time regarding experiments and improving communication between colleagues. For instance, in November 2023, Axtria introduced Axtria DataMAX Emerging Pharma, an AI-enabled SaaS solution designed for the commercialization and scaling of the operations of small and emerging biotech and pharmaceutical companies using data effectively.

North America dominated the AI in drug discovery market in 2023.

The AI in drug discovery market is studied for the five major regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The North American region dominated the AI in drug discovery market owing to factors such as the region's high per-capita healthcare expenditure, increased investment in healthcare technologies including AI, rising demand for personalized medicine driven by genomic data and patient-centric approaches, and the growing importance to reduce drug development costs & time, and focus for research on rare diseases. The growing focus on quality control, regulatory compliance, developed healthcare & drug discovery infrastructure, and the surging demand for digitalized technologies across North America further propels the growth. Moreover, the competitive landscape in North America encourages innovation among market players, driving continuous growth in technology and service offerings by various market vendors.

HIGHEST CAGR MARKET IN 2023
US FASTEST GROWING MARKET IN THE REGION

Recent Developments of AI in Drug Discovery Market

  • In September 2024, Insilico Medicine collaborated with Inimmune to leverage its proprietary AI platform, Chemistry42, in accelerating the discovery and development of next-generation immunotherapeutics.
  • In August 2024, Recursion and Exscientia plc announced an agreement, combining their technologies to enhance small molecule drug discovery. The integrated Recursion OS will enhance drug discovery through patient-centric target discovery, AI-driven design, quantum mechanics modeling, automated chemical synthesis, and more. The combined company plans to complete 10 clinical trials within 18 months. Exscientia shareholders will receive Recursion stock, with Recursion shareholders owning 74% of the combined company. The deal, worth USD 850 Million in cash, aims for USD 100 Million in annual synergies and is expected to close by early 2025
  • In June 2023, BenevolentAI collaborated with the Sheffield Institute for Translational Neuroscience (SITraN) at the University of Sheffield on this program, utilizing its patient-derived motor neuron/iAstrocyte co-culture systems and in vivo model expertise.
  • In January 2023 Google collaborated with Bayer AG to drive early drug discovery that will apply Google Cloud’s Tensor Processing Units (TPUs) to help accelerate and scale Bayer’s quantum chemistry calculations.

Key Market Players

KEY PLAYERS IN THE AI IN DRUG DISCOVERY MARKET INCLUDE

Want to explore hidden markets that can drive new revenue in Artificial Intelligence in Drug Discovery Market?

Scope of the Report

Report Metric Details
Market size available for years 2022-2029
Base Year Considered 2023
Forecast period 2024-2029
Forecast units Million/Billion (USD)
Segments covered Process, use case, therapeutic area, player type, AI tools, deployment, end user, and region
Geographies covered North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

 

Key Questions Addressed by the Report

Which are the top industry players in the AI in drug discovery market?
The top market players in the global AI in drug discovery market include The artificial intelligence (AI) in drug discovery market is dominated by key players. The prominent players operating in this market are NVIDIA Corporation (US), Exscientia (UK), Google (US), BenevolentAI (UK), Recursion (US), Insilico Medicine (US), Schrödinger, Inc. (US), Microsoft (US), Atomwise Inc. (US), Illumina, Inc. (US), Valo Health (US), Merck KGaA (Germany), IQVIA (US), CytoReason (Israel) AbCellera (US), and others.
Which deployment models have been included in the AI in drug discovery market report?
This report contains the following components:
  • On-premise
  • Cloud-based
  • SaaS-based
Which geographical region dominates the global AI in drug discovery market?
The global AI in drug discovery market is further bifurcated into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America holds a substantial share, and registers the highest growth rate during the forecast period.
Which end users have been included in the AI in drug discovery market report?
The report contains the following industry segments:
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations
  • Research Centers, Academic Institutes, & Government Organizations
What is the total CAGR expected to be recorded for the AI in drug discovery market during 2024-2029?
The CAGR is expected to record a CAGR of 29.9% from 2024-2029.

 

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Artificial Intelligence in Drug Discovery Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
39
RESEARCH METHODOLOGY
45
EXECUTIVE SUMMARY
62
PREMIUM INSIGHTS
68
MARKET OVERVIEW
72
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - Increasing number of cross-industry collaborations and partnerships
    - Rising need to reduce time and cost of drug discovery and development
    - Patent expiry of drugs and need for effective new leads
    - Growing utilization of AI to predict drug-target interactions for cancer therapy
    - Integration of AI-assisted multiomics in drug discovery
    - Growing focus on rare disease treatments for orphan drug development
    RESTRAINTS
    - Shortage of AI workforce and ambiguous regulatory guidelines for medical software
    OPPORTUNITIES
    - Leveraging AI for accelerated biotech drug discovery
    - Increased focus on drug discovery in emerging economies
    - Focus on developing human-aware AI systems
    - Growing use of AI in single-cell analysis
    - Easy identification of biomarker and disease subtypes from single-cell data
    - High demand for precision and personalized medicines
    CHALLENGES
    - Limited availability of quality data sets
    - Lack of advanced AI tools and training data sets
    - Computational constraints of advanced AI models
    - Lack of high-quality data sets for model training
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
  • 5.4 INDUSTRY TRENDS
    EVOLUTION OF AI IN DRUG DISCOVERY
    COMPUTER-AIDED DRUG DESIGN AND ARTIFICIAL INTELLIGENCE
  • 5.5 ECOSYSTEM ANALYSIS
  • 5.6 SUPPLY CHAIN ANALYSIS
  • 5.7 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - Dry lab services
    - Wet lab services
    COMPLEMENTARY TECHNOLOGIES
    - High-performance computing
    - Next-generation sequencing
    - Real-world evidence/Real-world data
    ADJACENT TECHNOLOGIES
    - Cloud computing
    - Blockchain technologies
    - Internet of things
  • 5.8 REGULATORY LANDSCAPE
    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    REGULATORY FRAMEWORK
  • 5.9 PRICING ANALYSIS
    INDICATIVE SELLING PRICE FOR DRUG DISCOVERY SOFTWARE AND SERVICES, BY REGION
    INDICATIVE PRICING ANALYSIS, BY PROCESS
  • 5.10 PORTER’S FIVE FORCES ANALYSIS
    INTENSITY OF COMPETITIVE RIVALRY
    BARGAINING POWER OF BUYERS
    THREAT OF SUBSTITUTES
    THREAT OF NEW ENTRANTS
    BARGAINING POWER OF SUPPLIERS
  • 5.11 KEY STAKEHOLDERS AND BUYING CRITERIA
    KEY STAKEHOLDERS IN BUYING PROCESS
    KEY BUYING CRITERIA
  • 5.12 PATENT ANALYSIS
    PATENT PUBLICATION TRENDS
    JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY
    MAJOR PATENTS IN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET
  • 5.13 UNMET NEEDS AND KEY PAIN POINTS
    UNMET NEEDS
    SINGLE-CELL ANALYSIS LANDSCAPE: KEY CHALLENGES AND PAIN POINTS IN DRUG DISCOVERY
    END-USER EXPECTATIONS
  • 5.14 KEY CONFERENCES & EVENTS, 2024–2025
  • 5.15 CASE STUDY ANALYSIS
  • 5.16 BUSINESS MODEL ANALYSIS
  • 5.17 INVESTMENT AND FUNDING SCENARIO
  • 5.18 IMPACT OF AI/GENERATIVE AI ON ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET
    TOP USE CASES AND MARKET POTENTIAL
    - Key use cases
    CASE STUDIES OF AI/GENERATIVE AI IMPLEMENTATION
    - Case study 1: Accelerated drug discovery with generative AI and streamlined workflows
    - Case study 2: Accelerating small-molecule drug discovery with generative AI
    IMPACT OF AI/GENERATIVE AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
    - AI in drug discovery market
    - Genomics and bioinformatics market
    - Life science analytics market
    USER READINESS AND IMPACT ASSESSMENT
    - User readiness
    - Impact assessment
  • 5.19 ARTIFICIAL INTELLIGENCE-DERIVED CLINICAL ASSETS
ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS
150
  • 6.1 INTRODUCTION
  • 6.2 TARGET IDENTIFICATION & SELECTION
    INCREASED DEMAND FOR PERSONALIZED MEDICINES AND HIGH INVESTMENT IN PHARMACEUTICAL R&D TO FUEL MARKET GROWTH
  • 6.3 TARGET VALIDATION
    RISING EMPHASIS ON AVOIDING LATE-STAGE FAILURE IN DRUG DISCOVERY TO BOOST MARKET GROWTH
  • 6.4 HIT IDENTIFICATION & PRIORITIZATION
    NEED FOR LARGE-SCALE DATA ANALYSIS TO DRIVE ADOPTION
  • 6.5 HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION
    HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION TO IMPROVE NEW DRUG POTENCY WITHOUT INCREASING LIPOPHILICITY
  • 6.6 LEAD OPTIMIZATION
    NEED FOR TRANSPARENT PRESENTATION AND ANALYSIS TO BOOST MARKET GROWTH
  • 6.7 CANDIDATE SELECTION & VALIDATION
    HIGH POSSIBILITY OF CLINICAL DRUG FAILURE TO SPUR ADOPTION OF CANDIDATE VALIDATION SERVICES
ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE
159
  • 7.1 INTRODUCTION
  • 7.2 UNDERSTANDING DISEASES
    INCREASED FOCUS ON UNDERSTANDING DISEASES TO IMPROVE RESEARCH DATA QUALITY AND QUANTITY
  • 7.3 DRUG REPURPOSING
    INCREASING NEED FOR COST-EFFECTIVE TREATMENTS AND RISING AVAILABILITY OF BIOMEDICAL DATA TO AID MARKET GROWTH
  • 7.4 DE NOVO DRUG DESIGN
    SMALL-MOLECULE DESIGN
    - Increasing use of virtual screening and simulation techniques to drive growth
    VACCINE DESIGN
    - Availability of well-validated AI tools to boost market growth
    ANTIBODY & OTHER BIOLOGICS DESIGN
    - Advancements in protein modeling to propel segment growth
  • 7.5 DRUG OPTIMIZATION
    SMALL-MOLECULE OPTIMIZATION
    - Leveraging generative models for identifying potential modifications in molecular structures to aid market growth
    VACCINE OPTIMIZATION
    - Effectively predicting vaccine formulations and adjusting delivery vectors to drive growth
    ANTIBODY & OTHER BIOLOGICS OPTIMIZATION
    - Increasing adoption of machine learning for predicting protein structures to augment segment growth
  • 7.6 SAFETY & TOXICITY
    FOCUS ON ADVANCED OFF-TARGET EFFECT PREDICTION, PK/PD SIMULATION, AND QSP MODELING TO DRIVE MARKET
ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA
172
  • 8.1 INTRODUCTION
  • 8.2 ONCOLOGY
    HIGH PREVALENCE OF CANCER AND SHORTAGE OF EFFECTIVE ONCOLOGY DRUGS TO PROPEL MARKET GROWTH
  • 8.3 INFECTIOUS DISEASES
    RISING EPIDEMIC OUTBREAKS TO BOOST DRUG DISCOVERY ACTIVITY
  • 8.4 NEUROLOGY
    COMPLEX DISEASE DIAGNOSIS AND TREATMENT TO INCREASE ADOPTION OF ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY
  • 8.5 METABOLIC DISEASES
    ROLE OF ARTIFICIAL INTELLIGENCE IN UNCOVERING SMALL-MOLECULE THERAPIES TO DRIVE ADOPTION
  • 8.6 CARDIOVASCULAR DISEASES
    SEDENTARY LIFESTYLES AND HIGH PREVALENCE OF OBESITY TO INCREASE NOVEL DRUG DEVELOPMENT FOR CARDIAC DISEASES
  • 8.7 IMMUNOLOGY
    GROWING DRUG PIPELINE FOR IMMUNOLOGICAL DISORDERS TO FAVOR MARKET GROWTH
  • 8.8 MENTAL HEALTH DISORDERS
    INCREASED OCCURRENCE OF MENTAL HEALTH DISEASES IN DEVELOPED ECONOMIES TO SPUR MARKET GROWTH
  • 8.9 OTHER THERAPEUTIC AREAS
ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE
182
  • 9.1 INTRODUCTION
  • 9.2 END-TO-END SOLUTION PROVIDERS
    END-TO-END SOLUTION PROVIDERS TO REDUCE NEED FOR MULTIPLE VENDORS AND ACCELERATE WORKFLOWS
  • 9.3 NICHE/POINT SOLUTION PROVIDERS
    ACCURATE, COST-EFFECTIVE, AND LESS TIME CONSUMPTION TO PROPEL MARKET GROWTH
  • 9.4 AI TECHNOLOGY PROVIDERS
    SPECIALIZED AI CAPABILITIES WITH FULL-SERVICE MANAGEMENT TO SUPPORT MARKET GROWTH
  • 9.5 BUSINESS PROCESS SERVICE PROVIDERS
    BETTER ACCESSIBILITY OF HIGH-QUALITY TOOLS AND LOWER DRUG DEVELOPMENT COSTS TO AID MARKET GROWTH
ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL
187
  • 10.1 INTRODUCTION
  • 10.2 MACHINE LEARNING
    DEEP LEARNING
    - Reduced number of errors and consistent management of data to augment market growth
    - Convolutional neural networks
    - Recurrent neural networks
    - Generative adversarial networks
    - Graph neural networks
    - Other deep learning technologies
    SUPERVISED LEARNING
    - Supervised learning to predict drug repositioning and manage high-dimensional datasets
    REINFORCEMENT LEARNING
    - Need to accelerate new molecules and maximize performance to augment segment growth
    UNSUPERVISED LEARNING
    - Unsupervised learning to perform complex tasks, uncover potential drug candidates, and optimize lead compounds
    OTHER MACHINE LEARNING TECHNOLOGIES
  • 10.3 NATURAL LANGUAGE PROCESSING
    NATURAL LANGUAGE PROCESSING TO IDENTIFY INFORMATION WITHIN UNSTRUCTURED DATA AND ACCELERATE DRUG DISCOVERY
  • 10.4 CONTEXT-AWARE PROCESSING & COMPUTING
    CONTEXT-AWARE COMPUTING TO IMPROVE PREDICTIONS OF PATIENT-SPECIFIC DRUG RESPONSES AND OPTIMIZE THERAPEUTIC INTERVENTIONS
  • 10.5 COMPUTER VISION
    COMPUTER VISION TO ENHANCE DRUG DISCOVERY THROUGH ADVANCED IMAGE PROCESSING
  • 10.6 IMAGE ANALYSIS
    BETTER DRUG DISCOVERY THROUGH IMAGE PROCESSING TECHNIQUES TO SUPPORT MARKET GROWTH
ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT
200
  • 11.1 INTRODUCTION
  • 11.2 ON-PREMISES DEPLOYMENT
    PROVISION OF MULTI-VENDOR ARCHITECTURE AND SECURITY BENEFITS TO DRIVE MARKET
  • 11.3 CLOUD-BASED DEPLOYMENT
    FOCUS ON RESEARCH COLLABORATIONS AND ELIMINATION OF SOFTWARE AND HARDWARE PURCHASING COSTS TO DRIVE MARKET
  • 11.4 SAAS-BASED DEPLOYMENT
    LOWER COSTS, BETTER SECURITY, AND EASIER ACCESS TO AUGMENT MARKET GROWTH
ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER
206
  • 12.1 INTRODUCTION
  • 12.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    RISING DEMAND FOR COST-EFFECTIVE DRUG DEVELOPMENT TO PROPEL MARKET GROWTH
  • 12.3 CONTRACT RESEARCH ORGANIZATIONS
    RISING NEED FOR OUTSOURCING IN PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRIES TO AID MARKET GROWTH
  • 12.4 RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES
    FOCUS ON DEVELOPING THERAPEUTIC STRATEGIES AND INNOVATIVE APPROACHES IN DRUG DISCOVERY TO AID MARKET GROWTH
ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY REGION
213
  • 13.1 INTRODUCTION
  • 13.2 NORTH AMERICA
    MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    US
    - US to dominate North American market during study period
    CANADA
    - Emergence of new AI-based startups and high health expenditure to support market growth
  • 13.3 EUROPE
    MACROECONOMIC OUTLOOK FOR EUROPE
    UK
    - Favorable government R&D funding to augment market growth
    GERMANY
    - Presence of advanced medical infrastructure and high focus on personalized medicines to drive market
    FRANCE
    - Strong government support and favorable strategies to propel market growth
    ITALY
    - Advanced pharmaceutical industry and increased focus on life science R&D to fuel market growth
    SPAIN
    - Favorable government initiatives and high investments by pharmaceutical companies to boost market growth
    REST OF EUROPE
  • 13.4 ASIA PACIFIC
    MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    JAPAN
    - High geriatric population and advanced pharmaceutical research to boost market growth
    CHINA
    - Increasing demand for generics and rising government investments to propel market growth
    INDIA
    - Developed IT infrastructure and favorable government initiatives to spur market growth
    REST OF ASIA PACIFIC
  • 13.5 LATIN AMERICA
    MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    BRAZIL
    - Growing biotechnology sector and increasing governmental initiatives to boost market growth
    MEXICO
    - Favorable government initiatives and high investments by pharmaceutical companies to support market growth
    REST OF LATIN AMERICA
  • 13.6 MIDDLE EAST & AFRICA
    MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
    GCC COUNTRIES
    - Increasing emphasis on personalized medicines and developing healthcare infrastructure to drive market
    REST OF MIDDLE EAST & AFRICA
COMPETITIVE LANDSCAPE
334
  • 14.1 INTRODUCTION
  • 14.2 KEY PLAYER STRATEGY/RIGHT TO WIN
    OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET
  • 14.3 REVENUE ANALYSIS, 2019–2023
  • 14.4 MARKET SHARE ANALYSIS, 2023
    RANKING OF KEY MARKET PLAYERS
  • 14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT: KEY PLAYERS, 2023
    - Company footprint
    - Use case footprint
    - Process footprint
    - Therapeutic area footprint
    - Player type footprint
    - Deployment mode footprint
    - Region footprint
  • 14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
  • 14.7 COMPANY VALUATION AND FINANCIAL METRICS
    FINANCIAL METRICS
    COMPANY VALUATION
  • 14.8 BRAND/PRODUCT COMPARISON
  • 14.9 COMPETITIVE SCENARIO
    PRODUCT AND SOLUTION LAUNCHES
    DEALS
    EXPANSIONS
    OTHER DEVELOPMENTS
COMPANY PROFILES
359
  • 15.1 KEY PLAYERS
    NVIDIA CORPORATION
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    - MnM view
    EXSCIENTIA
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    - MnM view
    GOOGLE
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    - MnM view
    RECURSION
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    - MnM view
    INSILICO MEDICINE
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    - MnM view
    SCHRÖDINGER, INC.
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    BENEVOLENTAI
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    MICROSOFT CORPORATION
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    ATOMWISE INC.
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    ILLUMINA, INC.
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    NUMEDII, INC.
    - Business overview
    - Products/Services/Solutions offered
    XTALPI INC.
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    IKTOS
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    TEMPUS
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    DEEP GENOMICS
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    VERGE GENOMICS
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    BENCHSCI
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    INSITRO
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    VALO HEALTH
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    BPGBIO, INC.
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    MERCK KGAA
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
  • 15.2 OTHER PLAYERS
    PREDICTIVE ONCOLOGY
    IQVIA INC.
    TENCENT HOLDINGS LIMITED
    CYTOREASON LTD.
    OWKIN, INC.
    CLOUD PHARMACEUTICALS
    EVAXION BIOTECH A/S
    STANDIGM INC.
    BIOAGE LABS
    ENVISAGENICS
    ABCELLERA
    CENTELLA
APPENDIX
466
  • 16.1 DISCUSSION GUIDE
  • 16.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 16.3 CUSTOMIZATION OPTIONS
  • 16.4 RELATED REPORTS
  • 16.5 AUTHOR DETAILS
LIST OF TABLES
 
  • TABLE 1 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: INCLUSIONS AND EXCLUSIONS
  • TABLE 2 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD, 2021–2023
  • TABLE 3 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: FACTOR ANALYSIS
  • TABLE 4 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: MARKET SIZING ASSUMPTIONS
  • TABLE 5 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: RISK ASSESSMENT
  • TABLE 6 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: IMPACT ANALYSIS
  • TABLE 7 INDICATIVE LIST OF COLLABORATIONS AND PARTNERSHIPS, 2021–2023
  • TABLE 8 INDICATIVE LIST OF DRUGS LOSING PATENTS IN 2023 AND 2024
  • TABLE 9 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: ROLE IN ECOSYSTEM
  • TABLE 10 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 11 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 12 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 13 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 14 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 15 NORTH AMERICA: REGULATORY FRAMEWORK
  • TABLE 16 EUROPE: REGULATORY FRAMEWORK
  • TABLE 17 ASIA PACIFIC: REGULATORY FRAMEWORK
  • TABLE 18 MIDDLE EAST & AFRICA: REGULATORY FRAMEWORK
  • TABLE 19 LATIN AMERICA: REGULATORY FRAMEWORK
  • TABLE 20 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: INDICATIVE SELLING PRICE, BY REGION, 2021–2023
  • TABLE 21 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: INDICATIVE PRICING, BY PROCESS, 2023
  • TABLE 22 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: PORTER’S FIVE FORCES ANALYSIS
  • TABLE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP THREE END USERS (%)
  • TABLE 24 KEY BUYING CRITERIA FOR TOP THREE END USERS
  • TABLE 25 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES FOR ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY
  • TABLE 26 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: LIST OF PATENTS/PATENT APPLICATIONS
  • TABLE 27 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: KEY CONFERENCES & EVENTS, JANUARY 2024–DECEMBER 2025
  • TABLE 28 CASE STUDY 1: LEVERAGING AI-DRIVEN PRECISION MEDICINE TO IDENTIFY PATIENT SUBTYPES AND NOVEL TARGETS IN INFLAMMATORY BOWEL DISEASE
  • TABLE 29 CASE STUDY 2: ARTIFICIAL INTELLIGENCE-DRIVEN DRUG DISCOVERY AND CO-DEVELOPMENT
  • TABLE 30 CASE STUDY 3: ADVANCING GENE THERAPY FOR RARE NEUROLOGICAL DISEASES
  • TABLE 31 CASE STUDY 4: ARTIFICIAL INTELLIGENCE DESIGN AND OPTIMIZATION OF EXS4318
  • TABLE 32 CASE STUDY 5: ARTIFICIAL INTELLIGENCE-DRIVEN DESIGN AND CLINICAL EVALUATION OF GTAEXS617
  • TABLE 33 KEY ARTIFICIAL INTELLIGENCE-DERIVED CLINICAL ASSETS, BY COMPANY
  • TABLE 34 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022–2029 (USD MILLION)
  • TABLE 35 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR TARGET IDENTIFICATION & SELECTION, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 36 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR TARGET VALIDATION, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 37 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR HIT IDENTIFICATION & PRIORITIZATION, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 38 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 39 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR LEAD OPTIMIZATION, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 40 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CANDIDATE SELECTION & VALIDATION, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 41 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022–2029 (USD MILLION)
  • TABLE 42 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 43 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG REPURPOSING, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 44 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 45 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 46 SMALL-MOLECULE DESIGN MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 47 VACCINE DESIGN MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 48 ANTIBODY & OTHER BIOLOGICS DESIGN MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 49 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 50 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 51 SMALL-MOLECULE OPTIMIZATION MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 52 VACCINE OPTIMIZATION MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 53 ANTIBODY & OTHER BIOLOGICS OPTIMIZATION MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 54 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SAFETY & TOXICITY, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 55 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 56 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR ONCOLOGY, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 57 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 58 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEUROLOGY, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 59 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 60 INDICATIVE LIST OF DEVELOPMENTS IN CARDIOVASCULAR DRUG DEVELOPMENT
  • TABLE 61 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 62 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMMUNOLOGY, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 63 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MENTAL HEALTH DISORDERS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 64 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 65 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022–2029 (USD MILLION)
  • TABLE 66 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR END-TO-END SOLUTION PROVIDERS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 67 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NICHE/POINT SOLUTION PROVIDERS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 68 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR AI TECHNOLOGY PROVIDERS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 69 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR BUSINESS PROCESS SERVICE PROVIDERS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 70 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022–2029 (USD MILLION)
  • TABLE 71 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 72 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 73 DEEP LEARNING MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 74 SUPERVISED LEARNING MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 75 REINFORCEMENT LEARNING MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 76 UNSUPERVISED LEARNING MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 77 OTHER MACHINE LEARNING TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 78 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NATURAL LANGUAGE PROCESSING, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 79 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTEXT-AWARE PROCESSING & COMPUTING, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 80 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR COMPUTER VISION, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 81 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMAGE ANALYSIS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 82 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022–2029 (USD MILLION)
  • TABLE 83 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR ON-PREMISES DEPLOYMENT, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 84 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CLOUD-BASED DEPLOYMENT, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 85 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SAAS-BASED DEPLOYMENT, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 86 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 87 INDICATIVE LIST OF DEVELOPMENTS RELATED TO ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY
  • TABLE 88 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 89 INDICATIVE LIST OF COLLABORATIONS WITH CONTRACT RESEARCH ORGANIZATIONS
  • TABLE 90 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 91 INDICATIVE LIST OF COLLABORATIONS IN RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES
  • TABLE 92 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 93 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 94 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 95 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS 2022–2029 (USD MILLION)
  • TABLE 96 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022–2029 (USD MILLION)
  • TABLE 97 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 98 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 99 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 100 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022–2029 (USD MILLION)
  • TABLE 101 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022–2029 (USD MILLION)
  • TABLE 102 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 103 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022–2029 (USD MILLION)
  • TABLE 104 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 105 US: INDICATIVE LIST OF STRATEGIC DEVELOPMENTS
  • TABLE 106 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS 2022–2029 (USD MILLION)
  • TABLE 107 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022–2029 (USD MILLION)
  • TABLE 108 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 109 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 110 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 111 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022–2029 (USD MILLION)
  • TABLE 112 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022–2029 (USD MILLION)
  • TABLE 113 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 114 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022–2029 (USD MILLION)
  • TABLE 115 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 116 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS 2022–2029 (USD MILLION)
  • TABLE 117 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022–2029 (USD MILLION)
  • TABLE 118 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 119 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 120 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 121 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022–2029 (USD MILLION)
  • TABLE 122 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022–2029 (USD MILLION)
  • TABLE 123 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 124 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022–2029 (USD MILLION)
  • TABLE 125 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 126 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY 2022–2029 (USD MILLION)
  • TABLE 127 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022–2029 (USD MILLION)
  • TABLE 128 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022–2029 (USD MILLION)
  • TABLE 129 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 130 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 131 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 132 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022–2029 (USD MILLION)
  • TABLE 133 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022–2029 (USD MILLION)
  • TABLE 134 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 135 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022–2029 (USD MILLION)
  • TABLE 136 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 137 UK: INDICATIVE LIST OF STRATEGIC DEVELOPMENTS
  • TABLE 138 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022–2029 (USD MILLION)
  • TABLE 139 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022–2029 (USD MILLION)
  • TABLE 140 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 141 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 142 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 143 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022–2029 (USD MILLION)
  • TABLE 144 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022–2029 (USD MILLION)
  • TABLE 145 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 146 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022–2029 (USD MILLION)
  • TABLE 147 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 148 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022–2029 (USD MILLION)
  • TABLE 149 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022–2029 (USD MILLION)
  • TABLE 150 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 151 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 152 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 153 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022–2029 (USD MILLION)
  • TABLE 154 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022–2029 (USD MILLION)
  • TABLE 155 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 156 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022–2029 (USD MILLION)
  • TABLE 157 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 158 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022–2029 (USD MILLION)
  • TABLE 159 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022–2029 (USD MILLION)
  • TABLE 160 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 161 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 162 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 163 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022–2029 (USD MILLION)
  • TABLE 164 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022–2029 (USD MILLION)
  • TABLE 165 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 166 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022–2029 (USD MILLION)
  • TABLE 167 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 168 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022–2029 (USD MILLION)
  • TABLE 169 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022–2029 (USD MILLION)
  • TABLE 170 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 171 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 172 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 173 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022–2029 (USD MILLION)
  • TABLE 174 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022–2029 (USD MILLION)
  • TABLE 175 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 176 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022–2029 (USD MILLION)
  • TABLE 177 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 178 SPAIN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022–2029 (USD MILLION)
  • TABLE 179 SPAIN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022–2029 (USD MILLION)
  • TABLE 180 SPAIN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 181 SPAIN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 182 SPAIN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 183 SPAIN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022–2029 (USD MILLION)
  • TABLE 184 SPAIN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022–2029 (USD MILLION)
  • TABLE 185 SPAIN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 186 SPAIN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022–2029 (USD MILLION)
  • TABLE 187 SPAIN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 188 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022–2029 (USD MILLION)
  • TABLE 189 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022–2029 (USD MILLION)
  • TABLE 190 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 191 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 192 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 193 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022–2029 (USD MILLION)
  • TABLE 194 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022–2029 (USD MILLION)
  • TABLE 195 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 196 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022–2029 (USD MILLION)
  • TABLE 197 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 198 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY 2022–2029 (USD MILLION)
  • TABLE 199 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022–2029 (USD MILLION)
  • TABLE 200 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022–2029 (USD MILLION)
  • TABLE 201 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 202 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 203 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 204 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022–2029 (USD MILLION)
  • TABLE 205 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022–2029 (USD MILLION)
  • TABLE 206 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 207 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022–2029 (USD MILLION)
  • TABLE 208 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 209 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022–2029 (USD MILLION)
  • TABLE 210 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022–2029 (USD MILLION)
  • TABLE 211 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 212 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 213 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 214 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022–2029 (USD MILLION)
  • TABLE 215 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022–2029 (USD MILLION)
  • TABLE 216 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 217 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022–2029 (USD MILLION)
  • TABLE 218 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 219 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022–2029 (USD MILLION)
  • TABLE 220 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022–2029 (USD MILLION)
  • TABLE 221 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 222 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 223 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 224 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022–2029 (USD MILLION)
  • TABLE 225 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022–2029 (USD MILLION)
  • TABLE 226 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 227 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022–2029 (USD MILLION)
  • TABLE 228 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 229 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022–2029 (USD MILLION)
  • TABLE 230 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022–2029 (USD MILLION)
  • TABLE 231 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 232 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 233 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 234 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022–2029 (USD MILLION)
  • TABLE 235 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022–2029 (USD MILLION)
  • TABLE 236 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 237 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022–2029 (USD MILLION)
  • TABLE 238 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 239 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022–2029 (USD MILLION)
  • TABLE 240 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022–2029 (USD MILLION)
  • TABLE 241 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 242 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 243 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 244 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022–2029 (USD MILLION)
  • TABLE 245 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022–2029 (USD MILLION)
  • TABLE 246 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 247 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022–2029 (USD MILLION)
  • TABLE 248 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 249 LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 250 LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022–2029 (USD MILLION)
  • TABLE 251 LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022–2029 (USD MILLION)
  • TABLE 252 LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 253 LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 254 LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 255 LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022–2029 (USD MILLION)
  • TABLE 256 LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022–2029 (USD MILLION)
  • TABLE 257 LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 258 LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022–2029 (USD MILLION)
  • TABLE 259 LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 260 BRAZIL: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022–2029 (USD MILLION)
  • TABLE 261 BRAZIL: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022–2029 (USD MILLION)
  • TABLE 262 BRAZIL: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 263 BRAZIL: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 264 BRAZIL: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 265 BRAZIL: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022–2029 (USD MILLION)
  • TABLE 266 BRAZIL: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022–2029 (USD MILLION)
  • TABLE 267 BRAZIL: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 268 BRAZIL: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022–2029 (USD MILLION)
  • TABLE 269 BRAZIL: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 270 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022–2029 (USD MILLION)
  • TABLE 271 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022–2029 (USD MILLION)
  • TABLE 272 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 273 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 274 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 275 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022–2029 (USD MILLION)
  • TABLE 276 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022–2029 (USD MILLION)
  • TABLE 277 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 278 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022–2029 (USD MILLION)
  • TABLE 279 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 280 REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022–2029 (USD MILLION)
  • TABLE 281 REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022–2029 (USD MILLION)
  • TABLE 282 REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 283 REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 284 REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 285 REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022–2029 (USD MILLION)
  • TABLE 286 REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022–2029 (USD MILLION)
  • TABLE 287 REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 288 REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022–2029 (USD MILLION)
  • TABLE 289 REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 290 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 291 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022–2029 (USD MILLION)
  • TABLE 292 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022–2029 (USD MILLION)
  • TABLE 293 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 294 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 295 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 296 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022–2029 (USD MILLION)
  • TABLE 297 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022–2029 (USD MILLION)
  • TABLE 298 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 299 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022–2029 (USD MILLION)
  • TABLE 300 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 301 GCC COUNTRIES: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022–2029 (USD MILLION)
  • TABLE 302 GCC COUNTRIES: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022–2029 (USD MILLION)
  • TABLE 303 GCC COUNTRIES: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 304 GCC COUNTRIES: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 305 GCC COUNTRIES: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 306 GCC COUNTRIES: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022–2029 (USD MILLION)
  • TABLE 307 GCC COUNTRIES: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022–2029 (USD MILLION)
  • TABLE 308 GCC COUNTRIES: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 309 GCC COUNTRIES: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022–2029 (USD MILLION)
  • TABLE 310 GCC COUNTRIES: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 311 REST OF MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022–2029 (USD MILLION)
  • TABLE 312 REST OF MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022–2029 (USD MILLION)
  • TABLE 313 REST OF MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 314 REST OF MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 315 REST OF MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 316 REST OF MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022–2029 (USD MILLION)
  • TABLE 317 REST OF MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022–2029 (USD MILLION)
  • TABLE 318 REST OF MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 319 REST OF MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022–2029 (USD MILLION)
  • TABLE 320 REST OF MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 321 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, JANUARY 2021–OCTOBER 2024
  • TABLE 322 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: DEGREE OF COMPETITION
  • TABLE 323 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: USE CASE FOOTPRINT
  • TABLE 324 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: PROCESS FOOTPRINT
  • TABLE 325 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: THERAPEUTIC AREA FOOTPRINT
  • TABLE 326 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: PLAYER TYPE FOOTPRINT
  • TABLE 327 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: DEPLOYMENT MODE FOOTPRINT
  • TABLE 328 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: REGION FOOTPRINT
  • TABLE 329 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS
  • TABLE 330 ARTIFICIAL INTELLIGENCE IN DRUG DEVELOPMENT MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS, BY REGION
  • TABLE 331 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: PRODUCT AND SOLUTION LAUNCHES, JANUARY 2021–OCTOBER 2024
  • TABLE 332 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: DEALS, JANUARY 2021–OCTOBER 2024
  • TABLE 333 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: EXPANSIONS, JANUARY 2021–OCTOBER 2024
  • TABLE 334 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: OTHER DEVELOPMENTS, JANUARY 2021–OCTOBER 2024
  • TABLE 335 NVIDIA CORPORATION: COMPANY OVERVIEW
  • TABLE 336 NVIDIA CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 337 NVIDIA CORPORATION: PRODUCT AND SERVICE LAUNCHES, JANUARY 2021–OCTOBER 2024
  • TABLE 338 NVIDIA CORPORATION: DEALS, JANUARY 2021–OCTOBER 2024
  • TABLE 339 EXSCIENTIA: COMPANY OVERVIEW
  • TABLE 340 EXSCIENTIA: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 341 EXSCIENTIA: SOLUTION LAUNCHES, JANUARY 2021–OCTOBER 2024
  • TABLE 342 EXSCIENTIA: DEALS, JANUARY 2021–OCTOBER 2024
  • TABLE 343 EXSCIENTIA: EXPANSIONS, JANUARY 2021–OCTOBER 2024
  • TABLE 344 EXSCIENTIA: OTHER DEVELOPMENTS, JANUARY 2021–OCTOBER 2024
  • TABLE 345 GOOGLE: COMPANY OVERVIEW
  • TABLE 346 GOOGLE: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 347 GOOGLE: SOLUTION LAUNCHES, JANUARY 2021–OCTOBER 2024
  • TABLE 348 GOOGLE: DEALS, JANUARY 2021–OCTOBER 2024
  • TABLE 349 GOOGLE: EXPANSIONS, JANUARY 2021–OCTOBER 2024
  • TABLE 350 RECURSION: COMPANY OVERVIEW
  • TABLE 351 RECURSION: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 352 RECURSION: SOLUTION LAUNCHES, JANUARY 2021–OCTOBER 2024
  • TABLE 353 RECURSION: DEALS, JANUARY 2021–OCTOBER 2024
  • TABLE 354 RECURSION: EXPANSIONS, JANUARY 2021–OCTOBER 2024
  • TABLE 355 INSILICO MEDICINE: COMPANY OVERVIEW
  • TABLE 356 INSILICO MEDICINE: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 357 INSILICO MEDICINE: PRODUCT AND SOLUTION LAUNCHES AND DEVELOPMENTS, JANUARY 2021–OCTOBER 2024
  • TABLE 358 INSILICO MEDICINE: DEALS, JANUARY 2021–OCTOBER 2024
  • TABLE 359 INSILICO MEDICINE: OTHER DEVELOPMENTS, JANUARY 2021–OCTOBER 2024
  • TABLE 360 SCHRÖDINGER, INC.: COMPANY OVERVIEW
  • TABLE 361 SCHRÖDINGER, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 362 SCHRÖDINGER, INC.: DEALS, JANUARY 2021–OCTOBER 2024
  • TABLE 363 SCHRÖDINGER, INC.: OTHER DEVELOPMENTS, JANUARY 2021–OCTOBER 2024
  • TABLE 364 BENEVOLENTAI: COMPANY OVERVIEW
  • TABLE 365 BENEVOLENTAI: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 366 BENEVOLENTAI: DEALS, JANUARY 2021–OCTOBER 2024
  • TABLE 367 MICROSOFT CORPORATION: COMPANY OVERVIEW
  • TABLE 368 MICROSOFT CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 369 MICROSOFT CORPORATION: DEALS, JANUARY 2021–OCTOBER 2024
  • TABLE 370 ATOMWISE INC.: COMPANY OVERVIEW
  • TABLE 371 ATOMWISE INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 372 ATOMWISE INC.: DEALS, JANUARY 2021–OCTOBER 2024
  • TABLE 373 ILLUMINA, INC.: COMPANY OVERVIEW
  • TABLE 374 ILLUMINA, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 375 ILLUMINA, INC.: SOLUTION LAUNCHES, JANUARY 2021–OCTOBER 2024
  • TABLE 376 ILLUMINA, INC.: DEALS, JANUARY 2021–OCTOBER 2024
  • TABLE 377 NUMEDII, INC.: COMPANY OVERVIEW
  • TABLE 378 NUMEDII, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 379 XTALPI INC.: COMPANY OVERVIEW
  • TABLE 380 XTALPI INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 381 XTALPI INC.: DEALS, JANUARY 2021–OCTOBER 2024
  • TABLE 382 IKTOS: COMPANY OVERVIEW
  • TABLE 383 IKTOS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 384 IKTOS: DEALS, JANUARY 2021–OCTOBER 2024
  • TABLE 385 IKTOS: OTHER DEVELOPMENTS, JANUARY 2021–OCTOBER 2024
  • TABLE 386 TEMPUS: COMPANY OVERVIEW
  • TABLE 387 TEMPUS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 388 TEMPUS: SOLUTION LAUNCHES, JANUARY 2021–OCTOBER 2024
  • TABLE 389 TEMPUS: DEALS, JANUARY 2021–OCTOBER 2024
  • TABLE 390 TEMPUS: EXPANSIONS, JANUARY 2021–OCTOBER 2024
  • TABLE 391 TEMPUS: OTHER DEVELOPMENTS, JANUARY 2021–OCTOBER 2024
  • TABLE 392 DEEP GENOMICS: COMPANY OVERVIEW
  • TABLE 393 DEEP GENOMICS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 394 DEEP GENOMICS: SOLUTION LAUNCHES, JANUARY 2021–OCTOBER 2024
  • TABLE 395 DEEP GENOMICS: DEALS, JANUARY 2021–OCTOBER 2024
  • TABLE 396 DEEP GENOMICS: OTHER DEVELOPMENTS, JANUARY 2021–OCTOBER 2024
  • TABLE 397 VERGE GENOMICS: COMPANY OVERVIEW
  • TABLE 398 VERGE GENOMICS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 399 VERGE GENOMICS: DEALS, JANUARY 2021–OCTOBER 2024
  • TABLE 400 BENCHSCI: COMPANY OVERVIEW
  • TABLE 401 BENCHSCI: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 402 BENCHSCI: SOLUTION LAUNCHES, JANUARY 2021–OCTOBER 2024
  • TABLE 403 BENCHSCI: DEALS, JANUARY 2021–OCTOBER 2024
  • TABLE 404 BENCHSCI: OTHER DEVELOPMENTS, JANUARY 2021–OCTOBER 2024
  • TABLE 405 INSITRO: COMPANY OVERVIEW
  • TABLE 406 INSITRO: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 407 INSITRO: DEALS, JANUARY 2021–OCTOBER 2024
  • TABLE 408 INSITRO: OTHER DEVELOPMENTS, JANUARY 2021–OCTOBER 2024
  • TABLE 409 VALO HEALTH: COMPANY OVERVIEW
  • TABLE 410 VALO HEALTH: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 411 VALO HEALTH: DEALS, JANUARY 2021–OCTOBER 2024
  • TABLE 412 VALO HEALTH: OTHER DEVELOPMENTS, JANUARY 2021–OCTOBER 2024
  • TABLE 413 BPGBIO, INC.: COMPANY OVERVIEW
  • TABLE 414 BPGBIO, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 415 BPGBIO, INC.: DEALS, JANUARY 2021–OCTOBER 2024
  • TABLE 416 MERCK KGAA: COMPANY OVERVIEW
  • TABLE 417 MERCK KGAA: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 418 MERCK KGAA: SOLUTION LAUNCHES, JANUARY 2021–OCTOBER 2024
  • TABLE 419 MERCK KGAA: DEALS, JANUARY 2021–OCTOBER 2024
  • TABLE 420 MERCK KGAA: EXPANSIONS, JANUARY 2021–OCTOBER 2024
  • TABLE 421 MERCK KGAA: OTHER DEVELOPMENTS, JANUARY 2021–OCTOBER 2024
  • TABLE 422 PREDICTIVE ONCOLOGY: COMPANY OVERVIEW
  • TABLE 423 IQVIA INC.: COMPANY OVERVIEW
  • TABLE 424 TENCENT HOLDINGS LIMITED: COMPANY OVERVIEW
  • TABLE 425 CYTOREASON LTD.: COMPANY OVERVIEW
  • TABLE 426 OWKIN, INC.: COMPANY OVERVIEW
  • TABLE 427 CLOUD PHARMACEUTICALS: COMPANY OVERVIEW
  • TABLE 428 EVAXION BIOTECH A/S: COMPANY OVERVIEW
  • TABLE 429 STANDIGM INC.: COMPANY OVERVIEW
  • TABLE 430 BIOAGE LABS: COMPANY OVERVIEW
  • TABLE 431 ENVISAGENICS: COMPANY OVERVIEW
  • TABLE 432 ABCELLERA: COMPANY OVERVIEW
  • TABLE 433 CENTELLA: COMPANY OVERVIEW
LIST OF FIGURES
 
  • FIGURE 1 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: SEGMENTS AND REGIONS CONSIDERED
  • FIGURE 2 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: YEARS CONSIDERED
  • FIGURE 3 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: RESEARCH DESIGN
  • FIGURE 4 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: KEY DATA FROM SECONDARY SOURCES
  • FIGURE 5 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: KEY PRIMARY SOURCES
  • FIGURE 6 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: KEY DATA FROM PRIMARY SOURCES
  • FIGURE 7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: KEY INDUSTRY INSIGHTS
  • FIGURE 8 BREAKDOWN OF PRIMARY INTERVIEWS: BY DEMAND SIDE, SUPPLY SIDE, DESIGNATION, AND REGION
  • FIGURE 9 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
  • FIGURE 10 SUPPLY-SIDE MARKET ESTIMATION: REVENUE SHARE ANALYSIS
  • FIGURE 11 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: REVENUE SHARE ANALYSIS ILLUSTRATION
  • FIGURE 12 BOTTOM-UP APPROACH: END-USER SPENDING ON ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY
  • FIGURE 13 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2024–2029)
  • FIGURE 14 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 15 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: TOP-DOWN APPROACH
  • FIGURE 16 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: DATA TRIANGULATION
  • FIGURE 17 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2024 VS. 2029 (USD MILLION)
  • FIGURE 18 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 19 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024 VS. 2029 (USD MILLION)
  • FIGURE 20 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 21 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024 VS. 2029 (USD MILLION)
  • FIGURE 22 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024 VS. 2029 (USD MILLION)
  • FIGURE 23 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
  • FIGURE 24 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: REGIONAL SNAPSHOT
  • FIGURE 25 INCREASING NUMBER OF CROSS-INDUSTRY COLLABORATIONS AND PARTNERSHIPS TO DRIVE MARKET
  • FIGURE 26 US AND PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES COMMANDED LARGEST MARKET SHARE IN 2023
  • FIGURE 27 INDIA TO REGISTER HIGHEST GROWTH RATE FROM 2024 TO 2029
  • FIGURE 28 NORTH AMERICA TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 29 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATES DURING STUDY PERIOD
  • FIGURE 30 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 31 COST OF GENOME ANALYSIS VS. LEVELS OF RAW DATA GENERATED, 2003–2023
  • FIGURE 32 APPROVAL OF PERSONALIZED MEDICINES BY US FDA, 2015–2023
  • FIGURE 33 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
  • FIGURE 34 EVOLUTION OF AI IN DRUG DISCOVERY MARKET
  • FIGURE 35 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: STRUCTURE-BASED DRUG DESIGNING
  • FIGURE 36 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 37 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 38 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: TYPES OF SERVICE
  • FIGURE 39 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: PORTER’S FIVE FORCES ANALYSIS
  • FIGURE 40 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS
  • FIGURE 41 KEY BUYING CRITERIA FOR TOP THREE END USERS
  • FIGURE 42 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR “AI IN DRUG DISCOVERY” PATENTS (JANUARY 2015–SEPTEMBER 2024)
  • FIGURE 43 MAJOR PATENTS IN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET (JANUARY 2015–SEPTEMBER 2024)
  • FIGURE 44 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: BUSINESS MODELS
  • FIGURE 45 BENEFITS OF HYBRID BUSINESS MODELS
  • FIGURE 46 SPECIALIZATION OF ARTIFICIAL INTELLIGENCE-BASED COMPANIES OVER TIME
  • FIGURE 47 FUNDING IN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, 2013–2022 (USD MILLION)
  • FIGURE 48 MARKET POTENTIAL OF AI/GENERATIVE AI IN ENHANCING LABORATORY INFORMATICS ACROSS INDUSTRIES
  • FIGURE 49 IMPACT OF AI/GENERATIVE AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
  • FIGURE 50 HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION SEGMENT HELD LARGEST MARKET SHARE IN 2023
  • FIGURE 51 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SNAPSHOT
  • FIGURE 52 DISTRIBUTION OF R&D COMPANIES, BY COUNTRY/REGION (2022 VS. 2023)
  • FIGURE 53 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SNAPSHOT
  • FIGURE 54 REVENUE ANALYSIS OF KEY PLAYERS IN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET (2019–2023)
  • FIGURE 55 MARKET SHARE ANALYSIS OF KEY PLAYERS IN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET (2023)
  • FIGURE 56 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: RANKING OF KEY MARKET PLAYERS (2023)
  • FIGURE 57 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 58 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: COMPANY FOOTPRINT
  • FIGURE 59 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 60 EV/EBITDA OF KEY VENDORS
  • FIGURE 61 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 62 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 63 NVIDIA CORPORATION: COMPANY SNAPSHOT
  • FIGURE 64 EXSCIENTIA: COMPANY SNAPSHOT
  • FIGURE 65 GOOGLE: COMPANY SNAPSHOT
  • FIGURE 66 RECURSION: COMPANY SNAPSHOT
  • FIGURE 67 SCHRÖDINGER, INC.: COMPANY SNAPSHOT
  • FIGURE 68 BENEVOLENTAI: COMPANY SNAPSHOT
  • FIGURE 69 MICROSOFT CORPORATION: COMPANY SNAPSHOT
  • FIGURE 70 ILLUMINA, INC.: COMPANY SNAPSHOT
  • FIGURE 71 MERCK KGAA: COMPANY SNAPSHOT

The study involved significant activities to estimate the current size of the artificial intelligence (AI) in drug discovery market. Exhaustive secondary research was done to collect information on artificial intelligence (AI) in drug discovery market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the artificial intelligence (AI) in drug doscovery market.

Secondary Research

This research study involved the wide use of secondary sources, directories, and databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva; white papers, annual reports, and companies’ house documents; investor presentations; and the SEC filings of companies. The market for the companies offering AI in drug discovery solutions is arrived at by secondary data available through paid and unpaid sources, analyzing the product portfolios of the major companies in the ecosystem, and rating the companies by their performance and quality. Various sources were referred to in the secondary research process to identify and collect information for this study. The secondary sources include annual reports, press releases, investor presentations of companies, white papers, journals, certified publications, and articles from recognized authors, directories, and databases.

Various secondary sources were referred to in the secondary research process to identify and collect information related to the study. These sources included annual reports, press releases, investor presentations of AI in drug discovery vendors, forums, certified publications, and whitepapers. The secondary research was used to obtain critical information on the industry’s value chain, the total pool of key players, market classification, and segmentation from the market and technology-oriented perspectives.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources are mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess prospects.

Primary research was conducted to identify segmentation types, industry trends, key players, and key market dynamics such as drivers, restraints, opportunities, challenges, industry trends, and strategies adopted by key players.

After the complete market engineering (calculations for market statistics, market breakdown, market size estimations, market forecasting, and data triangulation), extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. Primary research was also undertaken to identify the segmentation types, industry trends, competitive landscape of AI in drug discovery solutions offered by various market players, and key market dynamics, such as drivers, restraints, opportunities, challenges, industry trends, and key player strategies.

In the complete market engineering process, the top-down and bottom-up approaches and several data triangulation methods were extensively used to perform the market estimation and market forecasting for the overall market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was performed on the complete market engineering process to list the key information/insights throughout the report.

Breakdown of the Primary Respondents:

*Others include sales managers, marketing managers, and product managers.

Note: Tiers are defined based on a company’s total revenue, as of 2023: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the artificial intelligence (AI) in drug discovery market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and markets have been identified through extensive secondary research.
  • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Data Triangulation

After arriving at the overall market size—using the market size estimation processes—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and sub-segment, the data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the artificial intelligence (AI) in drug discovery market.

Market Definition

Artificial intelligence (AI) in drug discovery is the use of Al algorithms and techniques to improve the efficiency and effectiveness of the drug discovery process. Al can be used to automate tasks, analyze large datasets, and generate new insights that would be difficult or impossible to obtain using traditional methods. Al algorithms, particularly machine learning and deep learning models, are employed to analyze vast datasets on genetics, molecular structures, and biological interactions. These Al systems can predict potential drug candidates, assess their safety profiles, and optimize the drug development process.

AI in drug discovery enables faster target identification and in silico drug design. It identifies patterns in data to predict which compounds will be successful medicines. Al is still in the early stages of development in drug discovery, but it has the potential to revolutionize the process by automating tasks and analyzing large datasets. Al can create significant value in drug discovery through three main drivers: time and cost savings, increased probability of success, and novelty of both the molecular target and optimized therapeutic agent.

Stakeholders

  • AI Solution Providers
  • AI Platform Providers
  • Technology Providers
  • AI System Providers
  • Platform Providers
  • System Integrators
  • Pharmaceutical Companies
  • Biotechnology Companies and Start-ups
  • Drug Discovery Ventures
  • Contract Development and Manufacturing Organizations (CDMOs)
  • Contract Research Organizations (CROs)
  • Research Centers and Universities
  • Academic Institutes
  • Forums, Alliances, and Associations
  • Distributors
  • Venture Capitalists
  • Government Organizations
  • Institutional Investors and Investment Banks
  • Investors/Shareholders
  • Consulting Companies in the Drug Discovery Sector and Regulatory Consultants
  • Raw Material and Component Manufacturers
  • Hardware Manufacturers and Suppliers
  • Data Providers
  • Regulatory Agencies
  • Healthcare Providers
  • Patient Advocacy Groups
  • Ethical and Legal Experts

Report Objectives

  • To define, describe, and forecast the global artificial intelligence (AI) in drug discovery market based on by process, use case, therapeutic area, player type, tools, deployment, end user, and region
  • To provide detailed information regarding the factors influencing the growth of the market (such as the drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall artificial intelligence (AI) in drug discovery market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the artificial intelligence (AI) in drug discovery market in five main regions (along with their respective key countries): North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To provide key industry insights such as supply chain analysis, regulatory analysis, patent analysis, and impact of generative AI
  • To profile key players and comprehensively analyze their product portfolios, market positions, and core competencies in the market
  • To track and analyze competitive developments such as product & service launches; expansions; partnerships, agreements, and collaborations; and acquisitions in the artificial intelligence (AI) in drug discovery market
  • To track and analyze competitive developments such as product launches and enhancements, investments, partnerships, collaborations, agreements, joint ventures, funding, acquisitions, expansions, conferences, FDA clearances, sales contracts, alliances, and R&D activities of the leading players in the market
  • To benchmark players within the artificial intelligence (AI) in drug discovery market using the Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offering

Previous Versions of this Report

Artificial Intelligence / AI in Drug Discovery Market by Offering, Process (Target selection, Validation, Lead generation, optimization), Drug Design (Small molecule, Vaccine, Antibody, PK/PD), Dry Lab, Wet Lab (Single Cell analysis) & Region - Global Forecast to 2028

Report Code HIT 7445
Published in Nov, 2023, By MarketsandMarkets™

Artificial Intelligence/AI in Drug Discovery Market by Offering (Software, Service), Technology (Machine Learning, Deep Learning), Application (Cardiovascular, Metabolic, Neurodegenerative), End User (Pharma, Biotech,CROs) - Global Forecasts to 2027

Report Code HIT 7445
Published in Jun, 2022, By MarketsandMarkets™

Artificial Intelligence/AI in Drug Discovery Market by Offering (Software, Service), Technology (Machine Learning, Deep Learning), Application (Cardiovascular, Metabolic, Neurodegenerative), End User (Pharma, Biotech,CROs) - Global Forecasts to 2027

Report Code HIT 7445
Published in Nov, 2019, By MarketsandMarkets™
"Our USP is "providing game-changing business opportunities reports with free customization" - so please feel free to provide us with your specific areas of interest / business challenges in much greater detail !!"

We appreciate your interest in this report. Once you fill out the form, you'll be immediately directed to an exclusive solution tailored to your needs. This high-value offering can help boost your revenue by 30% - a must-see opportunity for anyone looking to maximize growth.


By clicking the "Submit" button, you are agreeing to the Terms of Use and Privacy Policy.

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Artificial Intelligence in Drug Discovery Market

Anthony

Jun, 2022

Which market segment is expected to shape the future of the AI in Drug Discovery Market?.

Adam

Jun, 2022

Which are the most innovative companies in AI in Drug Discovery Market?.

Mathew

Jun, 2022

What are the new trends and advancements in the AI in Drug Discovery Market?.

DMCA.com Protection Status